TC
SVA

TFS Capital’s Sinovac Biotech, Ltd SVA Stock Holding History

TFS Capital’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-26,662
Closed -$157K – 1024
2016
Q4 		$157K Buy
26,662
+10,979
+70% +$66K 0.04% 578
2016
Q3 		$93K Sell
15,683
-8,967
-36% -$52.7K 0.02% 660
2016
Q2 		$146K Buy
24,650
+11,451
+87% +$70.2K 0.03% 802
2016
Q1 		$84K Buy
+13,199
New +$79.2K 0.01% 911
2015
Q1 		– Sell
-10,881
Closed -$57K – 1328
2014
Q4 		$57K Sell
10,881
-78,297
-88% -$399K 0.01% 945
2014
Q3 		$429K Sell
89,178
-8,659
-9% -$46.5K 0.04% 643
2014
Q2 		$552K Buy
97,837
+54,778
+127% +$333K 0.04% 611
2014
Q1 		$310K Buy
43,059
+8,601
+25% +$57K 0.02% 1002
2013
Q4 		$211K Sell
34,458
-17,467
-34% -$105K 0.01% 1269
2013
Q3 		$311K Buy
51,925
+3,011
+6% +$14.4K 0.01% 1090
2013
Q2 		$192K Buy
+48,914
New +$182K 0.01% 1341

Other funds holding SVA

SA
SAIF Advisors Admiralty, Hong Kong $438M AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return
GP
GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TFS Capital's SVA Position: Q1 2017 in Review

TFS Capital sold out of Sinovac Biotech, Ltd (SVA) in Q1 2017, closing a stake of 26,662 shares — an estimated $157K sold.

TFS Capital first reported a position in SVA in Q2 2013 and held it in 11 quarters. The position peaked at $552K in Q2 2014. 35 funds tracked by Wall St. Rank hold SVA as of Q1 2017.

  • TFS Capital reported no remaining Sinovac Biotech, Ltd position as of Q1 2017 after selling out during the quarter.
  • TFS Capital sold 26,662 Sinovac Biotech, Ltd shares in Q1 2017, an estimated $157K.
  • TFS Capital first reported a position in Sinovac Biotech, Ltd in Q2 2013 and held it in 11 quarters.
  • TFS Capital's Sinovac Biotech, Ltd position peaked at $552K in Q2 2014.
  • 35 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q1 2017.

Based on TFS Capital's 13F filing for Q1 2017, filed 5 May 2017.